Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Payables (2019 - 2025)

Keros Therapeutics' Payables history spans 7 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Payables fell 57.26% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 57.26%, while the annual FY2025 figure was $2.0 million, 57.26% down from the prior year.
  • Payables reached $2.0 million in Q4 2025 per KROS's latest filing, down from $2.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $7.7 million in Q2 2022 to a low of $1.4 million in Q2 2021.
  • Average Payables over 5 years is $4.1 million, with a median of $4.0 million recorded in 2023.
  • Peak YoY movement for Payables: crashed 71.72% in 2021, then soared 458.31% in 2022.
  • A 5-year view of Payables shows it stood at $3.6 million in 2021, then dropped by 8.4% to $3.3 million in 2022, then soared by 63.22% to $5.4 million in 2023, then decreased by 15.56% to $4.6 million in 2024, then tumbled by 57.26% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Payables are $2.0 million (Q4 2025), $2.3 million (Q3 2025), and $5.3 million (Q2 2025).